24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gilead
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
08:50
Israel strikes Iran; explosions heard in Isfahan
20:16
Cyber decacorn Wiz in advanced negotiation to acquire Lacework for $150-200 million
19:47
Google lays off 28 employees for protesting against Israeli cloud contract
19:29
Full list of Israeli high-tech funding rounds in 2024
More stories
Buzz
Most popular
Daily
Weekly
1
Cyber decacorn Wiz in advanced negotiation to acquire Lacework for $150-200 million
2
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
3
The price of failure: Dutch company's chip monopoly born from a bad bet by Intel
4
Google employees arrested following protest over Israel ties at executive’s office
5
Cyber unicorn Armis acquiring Silk Security for $150 million
More news
Gilead
6 stories about Gilead
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall
16.01.18
|
Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
CTech’s Daily Israeli Tech News Roundup
10.12.17
|
CTech
Backlash against Trump’s Jerusalem declaration has reached Israeli tech. AmTrust is planning a listing on Tel Aviv Stock Exchange. Teva’s stock is up following news of more layoffs.
Generic Focus made Kite Pharma Founder Leave Teva
13.11.17
|
Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients
30.08.17
|
Dror Reich
With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?
Gilead To Buy Kite Pharma for $11.9 Billion
29.08.17
|
Dror Reich
The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales
Please ensure Javascript is enabled for purposes of
website accessibility